Shares of GlaxoSmithKline plc (ADR) (NYSE:GSK) ended Wednesday session in red amid volatile trading. The shares closed down -0.17 points or -0.39% at $43.82 with 3.08 million shares getting traded. Post opening the session at $43.73, the shares hit an intraday low of $43.73 and an intraday high of $44.02 and the price vacillated in this range throughout the day. The company has a market cap of $104.74 billion and the numbers of outstanding shares have been calculated to be 4.87 billion shares.
On September 4, 2016 GlaxoSmithKline plc (ADR) (GSK) and Innoviva, Inc. (INVA) announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM). This unique study, which reported headline results in May 2016, was designed to evaluate the effectiveness and safety of Relvar® Ellipta® in patients with chronic obstructive pulmonary disease (COPD), compared with their ‘usual care’ administered in an everyday clinical practice setting. Data from the study are being presented at the European Respiratory Society (ERS) International Congress on Sunday 4th September in London, (abstract number OA249).
For the primary endpoint in patients, who had exacerbated in the year before the study, treated with Relvar Ellipta 100/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’) there was a statistically significant reduction of 8.4% (p=0.025; 95% CI 1.1 to 15.2) in the rate of moderate or severe exacerbations compared with patients receiving ‘usual care’. The majority of these patients in the study on usual care were taking an inhaled corticosteroid (ICS) containing regimen (88%). A similar reduction in exacerbations with FF/VI was seen in those patients on a treatment that included an ICS/ long-acting beta2-agonists (LABA) at baseline (8.0%; p=0.047; 95% CI 0.11 to 15.4).
For the ITT population there were no differences observed between FF/VI and usual care on secondary outcomes measured including the time to first moderate or severe exacerbation and rate of severe exacerbations, the rate of secondary care healthcare contacts and COPD related primary care contacts. There were more primary care contacts overall on FF/VI (12.3% increase, 95% CI 5.4 to 19.6). The COPD Assessment Test (CAT), which measures the impact of disease on health status, demonstrated 45% of patients receiving FF/VI improved their CAT score by 2 or more, a clinically relevant improvement, compared to 36% in the usual care group (odds ratio 1.51, 95% CI, 1.28 to 1.77).
Shares of Novavax, Inc. (NASDAQ:NVAX) ended Wednesday session in green amid volatile trading. The shares closed up +0.06 points or 0.83% at $7.31 with 4.83 million shares getting traded. Post opening the session at $7.25, the shares hit an intraday low of $7.19 and an intraday high of $7.60 and the price vacillated in this range throughout the day. The company has a market cap of $2.11 billion and the numbers of outstanding shares have been calculated to be 271.19 million shares.
Novavax, Inc. (NVAX) announced it will host its 4th annual Investor and Analyst Meeting, Tuesday, October 11, 2016 from 9:00 a.m. – 11:00 a.m. ET in New York, NY.
Senior management will conduct a series of presentations to update analysts and investors on the Company`s ongoing clinical development programs. In addition, a key opinion leader will provide a clinical perspective on respiratory syncytial virus (RSV) disease.
Novavax expects to announce data from its pivotal Phase 3 trial of the RSV F Vaccine in older adults in the third quarter of 2016.
For additional information and registration, please email email@example.com or call 443-213-0506.
A live webcast of the presentations can be accessed under the “Investors”/ “Events” section of the Novavax website at novavax.com. Please allow extra time prior to the webcast to visit the site and download the streaming media software required to listen to the Internet broadcast. The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com. The event will be archived on the company`s website for 90 days.